(Utkast) Kommisjonens gjennomføringsbeslutning (EU) .../... om opphevelse av gjennomføringsbeslutning (EU) 2024/2930 om utsettelse av utløpsdatoen for godkjenningen av dazomet til bruk i biocidprodukter av type 8 i samsvar med europaparlaments- og rådsforordning (EU) nr. 528/2012
Biocider: opphevelse av utsettelse av utløpsdatoen for godkjenningen av dazomet til bruk i produkter av type 8
(Draft) Commission Implementing Decision (EU) .../... repealing Implementing Decision (EU) 2024/2930 postponing the expiry date of the approval of dazomet for use in biocidal products of product-type 8 in accordance with Regulation (EU) No 528/2012 of the European Parliament and of the Council
Utkast til kommisjonsbeslutning godkjent av komite (representanter for medlemslandene) og publisert i EUs komitologiregister 27.10.2025
Bakgrunn
(fra kommisjonsbeslutningen)
(1) Dazomet was included in Annex I to Directive 98/8/EC of the European Parliament and of the Council2 as an active substance for use in biocidal products of product-type 8. Pursuant to Article 86 of Regulation (EU) No 528/2012, it was therefore considered approved until 31 July 2022 under that Regulation subject to the conditions set out in Annex I to Directive 98/8/EC.
(2) On 26 January 2021, an application was submitted in accordance with Article 13(1) of Regulation (EU) No 528/2012 for the renewal of the approval of dazomet for use in biocidal products of product-type 8 (‘the application’). The application was evaluated by the competent authority of Belgium.
(3) Pursuant to Commission Implementing Decision (EU) 2021/12893 , the expiry date of approval of dazomet for use in biocidal products of product-type 8 was postponed to 31 January 2025. That expiry date was further postponed to 31 July 2026 by Commission Implementing Decision (EU) 2024/29304 in order to allow sufficient time for the examination of the application.
(4) Commission Implementing Regulation (EU) [Publication office please add here the number of this Regulation C(2025) 2500 once it is associated, along the whole Decision] renewed the approval of dazomet for use in biocidal products of producttype 8, subject to the conditions in the Annex to that Regulation, including the expiry date of approval. Therefore, it is appropriate to repeal Implementing Decision (EU) 2024/2930 postponing the expiry date of the approval of dazomet,